On August 7, Exelixis fell 5.7% in regular trading, trading at $53.44/share, with turnover of $102 million. The decline came as investors chose to lock in profits following the company's latest quarterly earnings release.

Exelixis reported earnings on August 5 with an adjusted EPS of $0.82, modestly above the consensus estimate of $0.79. Heading into the report, the market had high expectations for continued volume growth in core product Cabometyx and advancement of the pipeline, particularly zanzalintinib which is under FDA review. Despite the earnings beat, funds opted for profit-taking given the stock's prior run-up.

For context, consensus had projected quarterly revenue of approximately $636 million, representing 10.71% year-over-year growth, with adjusted EPS growth of over 40%. Recent catalysts included positive Phase III data for Cabometyx in neuroendocrine tumors showing 74% risk reduction, and a clinical development collaboration with Merck on the Stellar-316 trial in colorectal cancer.

Exelixis is an oncology-focused biopharmaceutical company specializing in small molecule cancer therapies, with cabozantinib-based products CABOMETYX and COMETRIQ as its commercial backbone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)